4-aminopyridine has been researched along with Recrudescence in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " To study this hypothesis, we chose an animal model comprising focal unilateral hippocampal injection of 4-aminopyridine (4-AP), which produced focal recurrent hippocampal seizures with secondary generalization in awake, behaving rats." | 7.85 | Mortality with brainstem seizures from focal 4-aminopyridine-induced recurrent hippocampal seizures. ( Carlen, PL; Del Campo, M; Devinsky, O; Genov, R; Montandon, G; Salam, MT, 2017) |
| "Episodic ataxia type 2 is an autosomal dominant channelopathy, caused by genetic variants in the voltage-dependent calcium channel a-1 subunit (CACNA1A), which is characterized by intermittent episodes of vertigo and ataxia." | 5.72 | The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2. ( Brieva-Ruiz, L; González-Mingot, C; López-Ortega, R, 2022) |
| " To study this hypothesis, we chose an animal model comprising focal unilateral hippocampal injection of 4-aminopyridine (4-AP), which produced focal recurrent hippocampal seizures with secondary generalization in awake, behaving rats." | 3.85 | Mortality with brainstem seizures from focal 4-aminopyridine-induced recurrent hippocampal seizures. ( Carlen, PL; Del Campo, M; Devinsky, O; Genov, R; Montandon, G; Salam, MT, 2017) |
| "Episodic ataxia type 2 is an autosomal dominant channelopathy, caused by genetic variants in the voltage-dependent calcium channel a-1 subunit (CACNA1A), which is characterized by intermittent episodes of vertigo and ataxia." | 1.72 | The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2. ( Brieva-Ruiz, L; González-Mingot, C; López-Ortega, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| González-Mingot, C | 1 |
| López-Ortega, R | 1 |
| Brieva-Ruiz, L | 1 |
| Salam, MT | 1 |
| Montandon, G | 1 |
| Genov, R | 1 |
| Devinsky, O | 1 |
| Del Campo, M | 1 |
| Carlen, PL | 1 |
| Gerardi, C | 1 |
| Bertele', V | 1 |
| Rossi, S | 1 |
| Garattini, S | 1 |
| Banzi, R | 1 |
| Harris, S | 2 |
| Ma, H | 2 |
| Zhao, M | 2 |
| Boorman, L | 2 |
| Zheng, Y | 1 |
| Kennerley, A | 2 |
| Bruyns-Haylett, M | 2 |
| Overton, PG | 2 |
| Berwick, J | 2 |
| Schwartz, TH | 2 |
| Montcuquet, A | 1 |
| Magy, L | 1 |
| Jung, S | 1 |
| Yang, H | 1 |
| Kim, BS | 1 |
| Chu, K | 1 |
| Lee, SK | 1 |
| Jeon, D | 1 |
| Chalk, CH | 1 |
| Murray, NM | 1 |
| Newsom-Davis, J | 1 |
| O'Neill, JH | 1 |
| Spiro, SG | 1 |
1 review available for 4-aminopyridine and Recrudescence
| Article | Year |
|---|---|
Preapproval and postapproval evidence on drugs for multiple sclerosis.
Topics: 4-Aminopyridine; Alemtuzumab; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; D | 2018 |
7 other studies available for 4-aminopyridine and Recrudescence
| Article | Year |
|---|---|
The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2.
Topics: 4-Aminopyridine; Acetazolamide; Adult; Ataxia; Cerebellar Ataxia; Female; Humans; Male; Middle Aged; | 2022 |
Mortality with brainstem seizures from focal 4-aminopyridine-induced recurrent hippocampal seizures.
Topics: 4-Aminopyridine; Animals; Brain Stem; Electroencephalography; Hippocampus; Male; Rats; Rats, Wistar; | 2017 |
Coupling between gamma-band power and cerebral blood volume during recurrent acute neocortical seizures.
Topics: 4-Aminopyridine; Animals; Blood Volume; Cerebrovascular Circulation; Convulsants; Electroencephalogr | 2014 |
Contralateral dissociation between neural activity and cerebral blood volume during recurrent acute focal neocortical seizures.
Topics: 4-Aminopyridine; Animals; Brain Mapping; Cerebrovascular Circulation; Disease Models, Animal; Electr | 2014 |
[Recurrence and de novo trigeminal neuralgia induced by fampridine].
Topics: 4-Aminopyridine; Adult; Aged; Female; Humans; Multiple Sclerosis; Recurrence; Trigeminal Neuralgia | 2015 |
The immunosuppressant cyclosporin A inhibits recurrent seizures in an experimental model of temporal lobe epilepsy.
Topics: 4-Aminopyridine; Animals; Cyclosporine; Electroencephalography; Epilepsy, Temporal Lobe; Hippocampus | 2012 |
Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma.
Topics: 4-Aminopyridine; Action Potentials; Adult; Aged; Amifampridine; Carcinoma, Small Cell; Combined Moda | 1990 |